Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07323329

Enrollment

165

Registered

2026-01-07

Start date

2025-10-10

Completion date

2026-11-12

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Infertility (IVF Patients)

Keywords

Growth hormone, Infertility, IVF patients, Ovarian reserve

Brief summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Interventions

DRUGSomatropin (4IU for 1 month) plus, folic acid 400 mcg per day.

Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.

DRUGDHEA plus folic acid 400mcg per day

Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day

DIETARY_SUPPLEMENTcontrol group

Patients will receive folic acid 400 mcg per day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

At least two of the following three criteria had to be present after maximal stimulation: 1. Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR). 2. ≤3 oocytes with a conventional stimulation protocol). 3. An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].

Exclusion criteria

1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction. 2. Any pelvic pathology such as hydrosalpinx, uterine anomaly. 3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia

Design outcomes

Primary

Measure	Time frame
The number of mature oocyte	12 weeks

Secondary

Measure	Time frame
pregnancy rate	12 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026